Skip to main content

Adenoviral mediated pro/anti angiogenesis gene therapy for osteoporosis and metastatic bone disease

Objective

The socio-economic problem to overcome is that for both diseases: osteoporosis and metastatic bone disease there is no satisfactorily treatment. The quality of life of these patients and their environment is greatly affected and their life expectancy is limited. This is particularly true for patients being diagnosed with bone metastasis where the average life expectancy shortens to 18 to 24 months. Both osteogenesis and bone metastasis are stimulated by angiogenesis which can be seen as a common denominator. In the case of osteoporosis one would like to enhance angiogenesis whereas in the case of tumour growth one wants to suppress angiogenesis. The specific research objectives are aimed at utilizing gene targeting and gene therapy novel technologies in order to:
i. Inhibit angiogenesis in metastatic bone disease
ii. Enhance bone formation in bone lesions and osteoporosis

Funding Scheme

EAW - Exploratory awards

Coordinator

INTROGENE B.V.
Address
72,Wassenaarseweg 72
2301 CA Leiden
Netherlands

Participants (1)

HADASSAH MEDICAL ORGANIZATION
Israel
Address
Kiryat Hadassah, Ein Kerem
91120 Jerusalem